Trans-arterial embolization (TAE) for Carcinoma, Renal Cell

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Alabama at Birmingham, Birmingham, AL
Carcinoma, Renal Cell+2 More
Trans-arterial embolization (TAE) - Procedure
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Multi-center, single arm, prospective trial to estimate safety, feasibility, technical outcomes, and clinical outcomes of percutaneous cryoablation with neo-adjuvant trans-arterial embolization of the tumor in patients with T1b renal cell carcinoma. Continuous safety monitoring will be performed with stopping rules for patient accrual or study continuation.

Eligible Conditions

  • Carcinoma, Renal Cell
  • Renal Cell Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 30-90days post procedure

30-90days post procedure
The number of patients experiencing major adverse events defined as anything grade C or above by Society of Interventional Radiology Guidelines.

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

RCC Participants
1 of 1
Experimental Treatment

25 Total Participants · 1 Treatment Group

Primary Treatment: Trans-arterial embolization (TAE) · No Placebo Group · N/A

RCC Participants
Procedure
Experimental Group · 1 Intervention: Trans-arterial embolization (TAE) · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 30-90days post procedure
Closest Location: University of Alabama at Birmingham · Birmingham, AL
Photo of university of alabama at birmingham 1Photo of university of alabama at birmingham 2Photo of university of alabama at birmingham 3
1991First Recorded Clinical Trial
10 TrialsResearching Carcinoma, Renal Cell
1070 CompletedClinical Trials

Who is running the clinical trial?

Varian, a Siemens Healthineers CompanyIndustry Sponsor
17 Previous Clinical Trials
6,010 Total Patients Enrolled
University of Alabama at BirminghamLead Sponsor
1,402 Previous Clinical Trials
2,211,038 Total Patients Enrolled
2 Trials studying Carcinoma, Renal Cell
45 Patients Enrolled for Carcinoma, Renal Cell
Andrew Gunn, MDPrincipal InvestigatorUniversity of Alabama at Birmingham

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are aged at least 18 years.
You are willing to comply with all study procedures and are available for the duration of the study.
You have a solid renal mass that is consistent with RCC on either ultrasound, MRI, or CT.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.